Advances with microRNAs in Parkinson's disease research

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1103-1113

  Ma, Liuqing ^a,b   Wei, Liangming ^b   Wu, Fei ^b   Hu, Zhenhua ^b   Liu, Zhenguo ^a   Yuan, Weien ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

synuclein; LRRK2; miRNA; miRNA based therapy; Pathophysiology

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; DOPAMINE; LENTIVIRUS VECTOR; LET 7; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 122; MICRORNA 133B; MICRORNA 153; MICRORNA 184; MICRORNA 34B; MICRORNA 34C; MICRORNA 433; MICRORNA 7; MIRAVIRSEN; MIRNA MIMIC; OLIGONUCLEOTIDE; RNA; RNA DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE FUNCTION; HEPATITIS C; HUMAN; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTITUTION THERAPY; SYMPTOM;

LRRK2; MIRNA; MIRNA-BASED THERAPY; PATHOPHYSIOLOGY; Α-SYNUCLEIN;

ANIMALS; DOPAMINE; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE;

EID: 84885049621     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S48500     Document Type: Review

References (106)

1. Robinson PA. Protein stability and aggregation in Parkinson's disease. Biochem J. 2008;413(1):1-13.
2. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744-1754.
3. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones, 1817.
4. D'Amelio M, Ragonese P, Sconzo G, Aridon P, Savettieri G. Parkinson's disease and cancer: insights for pathogenesis from epidemiology. Ann N Y Acad Sci. 2009;1155:324-334.
5. Harraz MM, Dawson TM, Dawson VL. MicroRNAs in Parkinson's disease. J Chem Neuroanat. 2011;42(2):127-130.
6. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010;42(9):781-785.
7. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302(5646):819-822.
8. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med. 2009;11:e22.
9. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41(12):1308-1312.
10. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
12. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175-205.
13. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051-4060.
14. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10): 775-789.
15. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13(12):1097-1101.
16. Lee YS, Nakahara K, Pham JW, et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell. 2004;117(1):69-81.
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
18. Abe M, Bonini NM. MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol. 2013;23(1):30-36.
19. Kuss AW, Chen W. MicroRNAs in brain function and disease. Curr Neurol Neurosci Rep. 2008;8(3):190-197.
20. Enciu AM, Popescu BO, Gheorghisan-Galateanu A. MicroRNAs in brain development and degeneration. Mol Biol Rep. 2012;39(3): 2243-2252.
21. Kosik KS. The neuronal microRNA system. Nat Rev Neurosci. 2006;7(12):911-920.
22. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-840.
23. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
24. Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics. 2011;43(10):571-580.
25. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci. 2004;24(30):6715-6723.
26. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16-27.
27. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature. 1997;388(6645): 839-840.
28. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97(2):571-576.
29. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's Disease. Neuron. 2003;40(3):453-456.
30. Mutez E, et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum Mutat. 2011;32(4):E2079-E2090.
31. Sekine T, et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov Disord. 2010;25(16):2871-2875.
32. Cullen V, et al. Acid beta-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011;69(6):940-953.
33. Yavich L, Tanila H, Vepsalainen S, Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci. 2004;24(49): 11165-11170.
34. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A. 2009;106(31):13052-13057.
35. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem. 2010;285(17):12726-12734.
36. Chen H, Shalom-Feuerstein R, Riley J, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394(4): 921-927.
37. Petrucelli L, O'Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002;36(6): 1007-1019.
38. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21(24): 9549-9560.
39. Jiang H, Wu YC, Nakamura M, et al. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2-and Sin-1-induced cell death. Neurobiol Aging. 2007;28(11):1709-1717.
40. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett. 2002;320(3):146-150.
41. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290-1297.
42. Lau P, de Strooper B. Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol. 2010;21(7):768-773.
43. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005;310(5755):1817-1821.
44. Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 2006;20(14):1885-1898.
45. Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. RNA. 2009;15(1):21-32.
46. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44(4):595-600.
47. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607.
48. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010;466(7306):637-641.
49. Girling R, Partridge JF, Bandara LR, et al. A new component of the transcription factor DRTF1/E2F. Nature. 1993;362(6415):83-87.
50. Ingram L, Munro S, Coutts A, La Thangue N. E2F-1 regulation by an unusual DNA damage-responsive DP partner subunit. Cell Death Differ. 2011;18(1):122-132.
51. Zhao C, Sun G, Li S, et al. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci U S A. 2010;107(5):1876-1881.
52. Cookson MR. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb Perspect Med. 2012;2(9):a009415.
53. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3): 302-305.
54. Illarioshkin SN, Periquet M, Rawal N, et al. Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism. Mov Disord. 2003;18(8):914-919.
55. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256-259.
56. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective Function of DJ-1 in Parkinson's Disease. Oxid Med Cell Longev. 2013;2013:683920.
57. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004;2(11):e362.
58. Demasi M, Davies KJ. Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett. 2003;542(1-3):89-94.
59. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron. 2003;39(6):889-909.
60. Billia F, Hauck L, Grothe D, et al. Parkinson-susceptibility gene DJ-1/PARK7 protects the murine heart from oxidative damage in vivo. Proc Natl Acad Sci U S A. 2013;110(15):6085-6090.
61. Irrcher I, Aleyasin H, Seifert EL, et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet. 2010;19(19):3734-3746.
62. Krebiehl G, Ruckerbauer S, Burbulla LF, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One. 2010;5(2):e9367.
63. Thomas KJ, McCoy MK, Blackinton J, et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet. 2011;20(1):40-50.
64. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem. 2012;121(5): 830-839.
65. Mandemakers W, Morais VA, De Strooper B. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci. 2007;120(Pt 10): 1707-1716.
66. Miñones-Moyano E, Porta S, Escaramís G, et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet. 2011;20(15):3067-3078.
67. Shapshak P. Molecule of the month: miRNA and Parkinson's disease protein PARK2. Bioinformation. 2013;9(8):381-382.
68. Saito Y, Saito H. MicroRNAs in cancers and neurodegenerative disorders. Front Genet. 2012;3:194.
69. Kim J, Inoue K, Ishii J, et al. A microRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317(5842):1220-1224.
70. Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32(4):199-206.
71. Van den Munckhof P, Luk KC, Ste-Marie L, et al. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development. 2003;130(11):2535-2542.
72. Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res. 2003;114(2):123-131.
73. Martinat C, Bacci JJ, Leete T, et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci U S A. 2006;103(8):2874-2879.
74. Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A. 2003;100(7):4245-4250.
75. Fuchs J, Mueller JC, Lichtner P, et al. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging. 2009;30(5):731-738.
76. Bergman O, Håkansson A, Westberg L, et al. PITX3 polymorphism is associated with early onset Parkinson's disease. Neurobiol Aging. 2010;31(1):114-117.
77. Li J, Dani JA, Le WD. The Role of Transcription Factor Pitx3 in Dopamine Neuron Development and Parkinson's Disease. Curr Top Med Chem. 2009;9(10):855-859.
78. Nelson PT, Wang WX, Rajeev BW. MicroRNAs (miRNAs) in Neurodegenerative Diseases. Brain Pathol. 2008;18(1):130-138.
79. Ohmachi S, Watanabe Y, Mikami T, et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun. 2000;277(2):355-360.
80. Ohmachi S, Mikami T, Konishi M, Miyake A, Itoh N. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through growth factor receptor-1c. J Neurosci Res. 2003;72(4):436-443.
81. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. Trends Genet. 2008;24(10):489-497.
82. van der Walt JM, Noureddine MA, Kittappa R, et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet. 2004;74(6):1121-1127.
83. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28(5): 1213-1223.
84. Davis TH, Cuellar TL, Koch SM, et al. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J Neurosci. 2008;28(17):4322-4330.
85. Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet. 2008;82(2): 283-289.
86. Wider C, Dachsel JC, Soto AI, et al. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov Disord. 2009;24(3):455-459.
87. de Mena L, Cardo LF, Coto E, et al. FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. Neurosci Lett. 2010;479(1):22-25.
88. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711-719.
89. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443-453.
90. Lewis J, Melrose H, Bumcrot D, et al. In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener. 2008;3:19.
91. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006;198(2):382-390.
92. Blow N. Small RNAs: delivering the future. Nature. 2007;450(7172): 1117-1120.
93. Mack G. MicroRNA gets down to business. Nat Biotechnol. 2007;25(6): 631-638.
94. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008;105(15): 5868-5873.
95. Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17(6):1053-1063.
96. Junn E, Mouradian, MM. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther. 2012;133(2): 142-150.
97. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem. 2009;284(4):1971-1981.
98. Hébert SS, Horré K, Nicolai L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A. 2008;105(17): 6415-6420.
99. Zhao X, He X, Han X, et al. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron. 2010;65(5):612-626.
100. Meister G, Landthaler M, Dorsett Y, Tuschl T. Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing. RNA. 2004;10(3):544-550.
101. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438(7068):685-689.
102. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896-899.
103. Elmén J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36(4):1153-1162.
104. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201.
105. Li Y, Kowdley KV. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics. 2012;10(5):246-253.
106. Asikainen S, Rudgalvyte M, Heikkinen L, et al. Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models. J Mol Neurosci. 2010;41(1):210-218.